Abstract 749P
Background
In the RUBY (NCT03981796) trial, dostarlimab (D)+carboplatin/paclitaxel (CP) demonstrated significant PFS improvement compared to placebo (PBO)+CP in pts with pA/rEC. PROs are reported here for the dMMR/MSI-H population.
Methods
Pts with pA/rEC were randomized 1:1 to D+CP or PBO+CP Q3W (6 cycles) followed by D or PBO monotherapy Q6W ≤3 years or disease progression. EORTC QLQ-C30 and EORTC QLQ-EN24 were secondary endpoints. PROs were administered at baseline (BL), day 1 of each cycle (C), end of treatment (EOT), and all follow-ups. Change (chg) from BL to EOT was calculated for assessed scales. Mixed models for repeated measures were used to generate least-squares means (LSM), adjusting for within-pt correlations across time points within a pt and controlling for BL values. Improvement is indicated by higher scores for QoL and functional scales and lower scores for symptom scales.
Results
Of 494 pts enrolled, 118 were dMMR/MSI-H. Mean BL scores and mean chg from BL to EOT for global QoL, functional scales, and select symptom are shown in the table. Mean chg from BL to EOT showed improvement in global QoL, emotional and social function, pain, and back/pelvis pain for D+CP. Only back/pelvis pain showed improvement for PBO+CP. Significant differences (LSM [standard error]) between arms were reported for chg from BL to EOT for QoL (14.7 [5.45]; P=0.008), role (12.7 [5.92]; P=0.032), emotional (14.3 [4.92]; P=0.004) and social function (13.5 [5.43]; P=0.014), and fatigue (-13.3 [5.84]; P=0.025).
Conclusions
Pts receiving D+CP demonstrated improvements in several QoL domains relative to BL at EOT, with significant improvements over PBO+CP, in global QoL, role, emotional, and social function, and fatigue. Dostarlimab+CP significantly improved PFS while maintaining QoL, further supporting its use as a standard of care in pts with dMMR/MSI-H pA/rEC. Table: 749P
D+CP | PBO+CP | |||
BL Mean (SD) | BL to EOT Mean chg (SD) | BL Mean (SD) | BL to EOT Mean chg (SD) | |
EORTC QLQ-C30 | ||||
Global QoL | 66.7 (25.9) | 3.0 (19.4) | 67.3 (23.9) | -11.1 (29.1) |
Physical F | 74.9 (21.8) | -5.0 (17.1) | 69.1 (23.3) | -6.1 (26.9) |
Role F | 66.6 (32.2) | 0.9 (29.7) | 72.9 (32.2) | -7.8 (36.6) |
Emotional F | 75.9 (18.1) | 9.2 (17.5) | 75.9 (20.1) | -6.7 (30.4) |
Cognitive F | 86.3 (20.7) | -1.5 (17.8) | 88.0 (19.3) | -9.3 (31.5) |
Social F | 74.5 (30.3) | 6.1 (34.7) | 80.2 (27.2) | -12.0 (33.8) |
Pain a | 32.3 (27.3) | -3.0 (29.7) | 32.3 (32.1) | 8.2 (32.8) |
Fatigue a | 33.9 (25.2) | -5.1 (26.9) | 35.1 (27.7) | 7.2 (36.0) |
EORTC QLQ-EN24 | ||||
Back and pelvis pain a | 35.3 (31.0) | -10.8 (24.0) | 36.5 (32.7) | -3.1 (38.3) |
aLower scores indicate reduced symptom severity F, function
Clinical trial identification
NCT01847274.
Editorial acknowledgement
Writing and editorial support, funded and coordinated by GSK, was provided by Shannon Morgan-Pelosi, PhD, and Mary C. Wiggin, of Ashfield MedComms, an Inizio company.
Legal entity responsible for the study
GSK.
Funding
GSK.
Disclosure
G. Valabrega: Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, AstraZeneca, Clovis Oncology, GSK, PharmaMar, Roche, Tesaro. M.A. Powell: Financial Interests, Personal, Speaker, Consultant, Advisor: GSK, Tesaro, Merck, Eisai, Clovis Oncology, AstraZeneca. S. Hietanen: Financial Interests, Personal, Other: GSK; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Orion Pharma; Financial Interests, Personal, Expert Testimony: AstraZeneca, GSK. E.M. Miller: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, GSK, Tempus; Financial Interests, Personal, Other: OncLive, Opinions in Gyn Malignancies. Z. Novák: Financial Interests, Personal, Speaker, Consultant, Advisor: Sofmedica, AstraZeneca, MSD, Preglem; Financial Interests, Personal, Advisory Board: Richter Gedeon; Financial Interests, Personal, Other: AstraZeneca; Financial Interests, Personal, Stocks/Shares: Richter Gedeon. R. Holloway: Financial Interests, Personal, Other: GSK, AstraZeneca, Clovis, Eisai, Merck; Financial Interests, Personal, Stocks or ownership: Genelux. D. Denschlag: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, GSK/Tesaro, Roche, Eisai Germany, MSD Oncology, MSD, Intuitive Surgical, KLS Martin; Financial Interests, Personal, Other, travel expenses: AstraZeneca; Financial Interests, Personal, Other: Roche. T. Myers: Financial Interests, Personal, Other: Immunogen. A.M. Thijs: Financial Interests, Institutional, Funding: Alkermes, AstraZeneca, Clovis, Esperas, IMV, ImmunoGen Inc., Karyopharm, Merck Sharp & Dohme, Mersana, Novocure GmbH, OncoQuest Pharmaceuticals, Pfizer, Roche, and Tesaro; Financial Interests, Personal, Speaker, Consultant, Advisor: Merck; Financial Interests, Personal, Other: Alkermes, AstraZeneca, Eisai, Eisai-Merck, and GSK. L. Gilbert: Financial Interests, Institutional, Funding: Alkermes, AstraZeneca, Clovis, Esperas, IMV, ImmunoGen Inc., Karyopharm, Merck Sharp & Dohme, Mersana, Novocure GmbH, OncoQuest Pharmaceuticals, Pfizer, Roche, Tesaro; Financial Interests, Personal, Speaker, Consultant, Advisor: Merck, AstraZeneca, Eisai, Eisai-Merck, GSK; Financial Interests, Personal, Other: Alkermes. L. Copeland: Financial Interests, Institutional, Funding: AbbVie, Advaxis, Agenus, Ajinomoto, Arcus Biosciences Inc., Array BioPharm, AstraZeneca, BeiGene USA Inc., BMS, Cerulean Pharma, Clovis Oncology, Deciphera Pharma, Eisai, EMD Serano, Ergomed Clinical Research, Exelixis, Genetech/Roache, Genmab, GSK, Hoffmann-LaRoche, Immunogen, Leap Therapeutics, Ludwig Institute of Pharmaceuticals, Merck, Mersana Therapeutics, Novocure, OncoQuest, PharmaMar USA, Pfizer, PRA International, Precision Therapeutics, Regeneron, Sanofi, Seattle Genetics, Serono, Stemcentrix, Sumitomo Dainippon Pharma Oncology, Sutro Biopharm, Tesaro (GSK), TRACON Pharm, Verastem; Financial Interests, Personal, Advisory Board: A28 Therapeutics, Celsion Corporation, Corcept Therapeutics, Elevar Therapeutics, GSK, Immunogen, Inx Med, Luzsana Biotechnology, Myriad Genetics, OncoNova, Rubius Therapeutics, Sorrento Therapeutics, Toray Industries, Inc., VBL Therapeutics; Financial Interests, Personal, Member: DMCC for Corcept Therapeutics. R. Gogoi: Financial Interests, Personal, Advisory Board: Pionyr Pharmaceuticals; Financial Interests, Personal, Other: Bausch + Lomb. N. Cloven: Financial Interests, Personal, Advisory Board: GSK, AstraZeneca, Toray Pharmaceuticals. O. Meyers, J. Garside: Financial Interests, Personal, Full or part-time Employment: GSK. M.R. Mirza: Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, Karyopharm, Merck, Roche, Zailab; Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK; Financial Interests, Personal, Member of Board of Directors: Karyopharm; Financial Interests, Personal, Stocks/Shares: Karyopharm; Financial Interests, Institutional, Research Grant: GSK, AstraZeneca, ultimovacs, Apexigen; Financial Interests, Institutional, Trial Chair: Deciphera; Non-Financial Interests, Advisory Role: Ultimovacs, Apexigen. D. Black: Financial Interests, Institutional, Funding: GSK; Financial Interests, Personal, Membership or affiliation: GOG Partners Investigational Council; Financial Interests, Personal, Ownership Interest: Trials365, LLC. All other authors have declared no conflicts of interest.
Resources from the same session
800P - Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients
Presenter: Sarah Howlett
Session: Poster session 11
802P - Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
Presenter: Frederik Marmé
Session: Poster session 11
803P - Pre-treatment systemic inflammatory markers predict survival in endometrial cancer cases: A Japanese gynaecologic oncology group 2043 exploratory data analysis
Presenter: Shin Nishio
Session: Poster session 11
805P - Tumor-informed ctDNA detection as a predictive marker for postoperative residual disease in epithelial ovarian cancer: A feasibility study
Presenter: Christoph Grimm
Session: Poster session 11
806P - Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers
Presenter: Ainhoa Madariaga Urrutia
Session: Poster session 11
807P - Predicting surgical outcomes in patients with advanced ovarian cancer through MRI based preoperative evaluation
Presenter: Shujuan Liu
Session: Poster session 11
808P - Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for monitoring treatment response and for detecting relapse in locally advanced cervical cancer
Presenter: Lars Sivars
Session: Poster session 11
809P - Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship
Presenter: jiangrong wang
Session: Poster session 11
810P - The influence of preoperative conization (pc) to patient’s (pts) outcome and tumor biology of cervical cancer (CC)
Presenter: Dimitra Trantaki
Session: Poster session 11
811P - Epidemiological landscape of cervical cancer in Latin America: EVITA LATAM (LACOG 0820)
Presenter: Graziela Zibetti Dal Molin
Session: Poster session 11